RecruitingNCT06862856

Flotufolastat F 18 PET in Men With Very Low PSA Recurrence

A Prospective Study of Flotufolastat F 18 Positron Emission Tomography in Men With Very Low Prostate Specific Antigen Recurrence

Sponsor

Massachusetts General Hospital

Enrollment

50 participants

Start Date

May 20, 2025

Study Type

OBSERVATIONAL

Conditions

Prostate Cancer (Adenocarcinoma)Prostate Specific Antigen

Summary

The purpose of this study is to assess detection rate of flotufolastat F 18 positron emission tomography (PET) for low prostate specific antigen (PSA) recurrence of prostate cancer (PC) following radical prostatectomy.

Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is evaluating a specialized PET scan called flotufolastat F 18 (a PSMA PET scan) to detect where prostate cancer has returned in men who have had a very slight rise in PSA (a blood marker for prostate cancer) after having their prostate surgically removed. **You may be eligible if...** - You are 18 or older, male - You have had your prostate surgically removed (radical prostatectomy) - Your PSA has risen after surgery but is very low (0.20 ng/mL or less) - It has been at least 6 weeks since your surgery - A PSMA PET scan has already been ordered as part of your standard care **You may NOT be eligible if...** - Your PSA is above 0.20 ng/mL - You have been on hormone therapy (ADT) within the last 16 weeks - You have not had the required PET scan as part of your care Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.